This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Novartis Ag. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Innovations in Influenza Vaccines by Klaus Stöhr
Introduction
Klaus Stöhr is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of vaccine development, particularly in the area of influenza protection. With a total of 2 patents, his work has been instrumental in advancing public health.
Latest Patents
Stöhr's latest patents focus on innovative vaccines for protecting against influenza. One of his patents describes a vaccine containing a H1 subtype influenza A virus hemagglutinin, which can be either unadjuvanted or adjuvanted without using an oil-in-water emulsion adjuvant. This vaccine is designed to immunize patients against swine flu and may be monovalent. It can also include two different H1 subtype influenza A virus hemagglutinins, with specific relationships to designated sequences. Another patent details a live attenuated influenza vaccine that contains a H1 subtype influenza A strain, with its hemagglutinin closely related to a specific sequence. These innovations represent a significant step forward in the fight against influenza.
Career Highlights
Klaus Stöhr has had a distinguished career, working with Novartis AG, a leading global healthcare company. His expertise in vaccine development has positioned him as a key figure in the industry. His contributions have not only advanced scientific understanding but have also had a direct impact on public health initiatives.
Collaborations
Throughout his career, Stöhr has collaborated with notable colleagues, including Philip R. Dormitzer and Giuseppe Del Giudice. These partnerships have fostered innovation and have been crucial in the development of effective influenza vaccines.
Conclusion
Klaus Stöhr's work in the field of influenza vaccines exemplifies the importance of innovation in public health. His patents and collaborations highlight his commitment to advancing vaccine technology and protecting communities from infectious diseases.